Merck in talks with NewLink to scale up Ebola vaccine production: Bloomberg

Ebolavirus under an electron microscope--Courtesy of CDC

Merck ($MRK) may soon be the next Big Pharma to step into the Ebola vaccine arena. According to Bloomberg, it's in talks with Iowa's NewLink Genetics ($NLNK) to pitch in with the manufacturing of the company's candidate, currently in Phase I trials in the U.S. and Canada. The New Jersey giant would join peers GlaxoSmithKline ($GSK) and Johnson & Johnson ($JNJ) in the Ebola vaccine race; both of those companies are currently developing prospects of their own. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.